IN SIGNO - Identification of Novel molecules Supporting the Impact of Beta-lactams against clinically-relevant Gram-negative multidrug resistant Organisms

The IN SIGNO project, coordinated by Professor Nicasio Mancini and funded by the Regional Foundation for Biomedical Research, addresses the problem of antibiotic resistance through the identification of new antibiotic adjuvants that could be used in combination with β-lactams against multidrug-resistant Gram-negative bacteria. The research activity of The Protein Factory 2.0 involves the production of several β-lactamases identified from pathogens isolated from patients, as well as investigating the potential inhibitory action of newly identified compounds that could be used as leading molecules for the development of new antibiotic adjuvants.